|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma:When and how?显示文摘Hilar cholangiocarcinoma (hCCA) is a primary liver tumor associated with a dimprognosis. The role of preoperative and palliative biliary drainage has long beendebated. The most common techniques are endoscopic retrograde cholangiopancreatography(ERCP) and percutaneous transhepatic biliary drainage (PTBD);however, recently developed endoscopic ultrasound-assisted methods are gainingmore atention. Selecting the best available method in any specific scenario iscrucial, yet sometimes challenging. Thus, this review aimed to discuss theavailable techniques, indications, perks, pitfalls, and timing-related issues in themanagement of hCCA. In a preoperative setting, PTBD appears to have someadvantages: low risk of postprocedural complications (namely cholangitis) andbetter priming for surgery. For palliative purposes, we propose ERCP/PTBDdepending on the experience of the operators, but also on other factors: the levelof bilirubin (if very high, rather PTBD), length of the stenosis and the presence ofcholangitis (PTBD), ERCP failure, or altered biliary anatomy. | Tudor Mocan Adelina Horhat Emil Mois Florin Graur Cristian Tefas Rares Craciun Iuliana Nenu Mihaela Spârchez Zeno Sparchez | 2021 | World Journal of Gastrointestinal Oncology2021，13，12： | 3 |
| 2 | Novel approaches in search for biomarkers of cholangiocarcinoma显示文摘Cholangiocarcinoma(CCA)arises from the ductular epithelium of the biliary tree,either within the liver(intrahepatic CCA)or more commonly from the extrahepatic bile ducts(extrahepatic CCA).This disease has a poor prognosis and a growing worldwide prevalence.The poor outcomes of CCA are partially explained by the fact that a final diagnosis is challenging,especially the differential diagnosis between hepatocellular carcinoma and intrahepatic CCA,or distal CCA and pancreatic head adenocarcinoma.Most patients present with an advanced disease,unresectable disease,and there is a lack in non-surgical therapeutic modalities.Not least,there is an acute lack of prognostic biomarkers which further complicates disease management.Therefore,there is a dire need to find alternative diagnostic and follow-up pathways that can lead to an accurate result,either singlehandedly or combined with other methods.In the'-omics'era,this goal can be attained by various means,as it has been successfully demonstrated in other primary tumors.Numerous variants can reach a biomarker status ranging from circulating nucleic acids to proteins,metabolites,extracellular vesicles,and ultimately circulating tumor cells.However,given the relatively heterogeneous data,extracting clinical meaning from the inconsequential noise might become a tall task.The current review aims to navigate the nascent waters of the non-invasive approach to CCA and provide an evidence-based input to aid clinical decisions and provide grounds for future research. | Lavinia-Patricia Mocan Maria Ilieș Carmen Stanca Melincovici Mihaela Spârchez RareșCrăciun Iuliana Nenu Adelina Horhat Cristian Tefas Zeno Spârchez Cristina Adela Iuga Tudor Mocan Carmen Mihaela Mihu | 2022 | World Journal of Gastroenterology2022，28，15： | 1 |
| 3 | Separation performance of sub-micron silica particles by electrical hydrocyclone显示文摘 | Romanus Krisantus Tue Nenu Hideto Yoshida Kunihiro Fukui Tetsuya Yamamoto | 2009 | Powder Technology2009，，2： | 1 |
| 4 | Single-site heterogeneous Cr-based catalyst for the selective trimerisation of ethylene显示文摘 | NENU C N WECKHUYSEN B M | 2005 | Chem Commun2005，，14： | 1 |
| 5 | Effect of current density on reduction coupling of actone显示文摘 | Lete Cecilia Nenu Cristina | 1998 | Rev Chim1998，49，4： | 1 |
| 6 | Risk Management in Supplier Networks 显示文摘 | HALLIKASJ KARVONEN I PULKKI- NENU | 2004 | Intemational Journal of Produc- tion Economics2004，，90： | 1 |
| 7 | Combined treatments in hepatocellular carcinoma:Time to put them in the guidelines?显示文摘The time for battling cancer has never been more suitable than nowadays and fortunately against hepatocellular carcinoma(HCC)we do have a far-reaching arsenal.Moreover,because liver cancer comprises a plethora of stages-from very early to advanced disease and with many treatment options–from surgery to immunotherapy trials–it leaves the clinician a wide range of options.The scope of our review is to throw light on combination treatments that seem to be beyond guidelines and to highlight these using evidence-based analysis of the most frequently used combination therapies,discussing their advantages and flaws in comparison to the current standard of care.One particular combination therapy seems to be in the forefront:Transarterial chemoembolization plus ablation for medium-size non-resectable HCC(3-5 cm),which is currently at the frontier between Barcelona Clinic Liver Cancer classification A and B.Not only does it improve the outcome in contrast to each individual therapy,but it also seems to have similar results to surgery.Also,the abundance of immune checkpoint inhibitors that have appeared lately in clinical trials are bringing promising results against HCC.Although the path of combination therapies in HCC is still filled with uncertainty and caveats,in the following years the hepatology and oncology fields could witness an HCC guideline revolution. | Zeno Sparchez Pompilia Radu Adrian Bartos Iuliana Nenu Rares Craciun Tudor Mocan Adelina Horhat Mihaela Spârchez Jean-François Dufour | 2021 | World Journal of Gastrointestinal Oncology2021，13，12： | 1 |
| 8 | Ni(2,2'-bipyridine)2Cl2 encapsulated in Y zeolite new catalyst for ethylene dimerization显示文摘 | Zavoianu R Nenu C E Angelescu E | 2005 | Catalysis Communications2005，6，6： | 1 |
| 9 | Comparison of separation performance between single and two inlets hydrocyclones显示文摘 | Nenu R Yoshida H | 2009 | Advanced Powder Technol- ogy2009，20，2： | 1 |
| 10 | ABSTRACTS显示文摘 | Michela PICCIN(IHAC,NENU,Changchun) | 2018 | Journal of Ancient Civilizations2018，33，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员